Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 100 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Ahmed K.

United States

USD 100 /hr

Genomic Risk Modeling & Biobank Analytics Specialist (MD-PhD)

Profile Summary

I am an MD-PhD specializing in precision medicine and healthcare machine learning, with expertise in integrating polygenic risk scores and EHR data for clinically actionable risk prediction.

Subject Matter Expertise

• ☆ Computational Biology
• ☆ Biostatistics
• ☆ Molecular Biology
• ☆ Omics
• ☆ Genomics
• ☆ Data Analysis
• ☆ Predictive Modeling & Analytics
• ☆ Machine Learning
• ☆ Artificial Intelligence
• ☆ Python
• ☆ R
• ☆ Endocrinology
• ☆ Diabetes

Services

• Writing
• Research
• Consulting
• Data & AI

Writing Medical Writing

Research Scientific and Technical Research

Consulting Scientific and Technical Consulting

Data & AI Predictive Modeling, Algorithm Design-ML, Data Visualization, Data Processing, Data Insights

Work Experience

Genomic Medicine Fellow

University of Alabama at Birmingham

August 2025 - Present

Graduate Research Scientist

Scripps Research

January 2021 - July 2025

Clinical Research Fellow

The University of Texas Health Science Center at San Antonio

July 2018 - December 2020

Education

PhD

The Scripps Research Institute - United States

January 2021 - May 2025

Medical Degree (MD)

Zagazig University - Egypt

September 2009 - March 2017

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Ahmed Khattab, Shang-Fu Chen, Hossein Javedani Sadaei, Nathan E. Wineinger, Ali Torkamani (2026). Development and validation of a two-stage machine learning model for personalised type 2 diabetes screening in the All of Us Research Program and UK Biobank . BMJ Open.

Ahmed Khattab, Siham Abdelgani, John M. Adams, Fahd Al-Mulla, Mohamed Abu-Farha, Gozde Baskoy, Jehad Abubaker, Aurora Merovci, Ralph A. DeFronzo, Renata Belfort De Aguiar, et al. (2025). Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate: A Randomized Trial . Diabetes.

Ahmed Khattab, Shang-Fu Chen, Nathan Wineinger, Ali Torkamani (2025). AoUPRS: A cost-effective and versatile PRS calculator for the All of Us Program . BMC Genomics.

Ahmed Khattab, Shang-Fu Chen, Nathan Wineinger, Ali Torkamani (2025). AoUPRS: A cost-effective and versatile PRS calculator for the All of Us Program . BMC Genomics.

Ahmed Khattab, Shang-Fu Chen, Sang Eun Lee, Hossein Javedani Sadaei, Jun-Bean Park, Jei-Fu Chen, Corneliu Henegar, Nathan E. Wineinger, Evan D. Muse, Ali Torkamani (2025). Meta-prediction of coronary artery disease risk . Nature Medicine.

Ahmed Khattab, Siham Abdelgani, John Adams, Gozde Baskoy, Curtis Triplitt, Ralph A. DeFronzo, Muhammad Abdul‐Ghani (2024). The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals . Diabetes, Obesity and Metabolism.

Abdelgani S, Khattab A, Adams J, Baskoy G, Brown M, Clarke G, Larvenenko O, DeFronzo RA, Abdul-Ghani M (2024). Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes . Diabetes care.

AHMED KHATTAB, SHANG-FU CHEN, HOSSEIN J. SADAEI, ALI TORKAMANI (2023). 1288-P: Predictive Modeling of Type 2 Diabetes and Complications Using Machine Learning . Diabetes.

Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients @article{10.2337/dc22-0885,author={Abdelgani, Siham and Khattab, Ahmed and Adams, John and Abu-Farha, Mohamed and Daniele, Guisepe and Al-Mulla, Fahd and Del Prato, Stefano and DeFronzo, Ralph A. and Abdul-Ghani, Muhammad},title={{Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients}},journal={Diabetes Care},year={2023},month={03},abstract={{To examine the mechanisms responsible for the increase in glucose and ketone production caused by empagliflozin in patients with type 2 diabetes mellitus (T2DM).Twelve subjects with T2DM participated in two studies performed in random order. In study 1, endogenous glucose production (EGP) was measured with 8-h infusion of 6,6,D2-glucose. Three hours after the start of 6,6,D2-glucose infusion, subjects ingested 25 mg empagliflozin (n = 8) or placebo (n = 4), and norepinephrine (NE) turnover was measured before and after empagliflozin ingestion with 3H-NE infusion. Study 2 was similar to study 1 but performed under pancreatic clamp conditions.When empagliflozin was ingested under fasting conditions, EGP increased by 31\\% in association with a decrease in plasma glucose (−34 mg/dL) and insulin (−52\\%) concentrations and increases in plasma glucagon (+19\\%), free fatty acid (FFA) (+29\\%), and β-hydroxybutyrate (+48\\%) concentrations. When empagliflozin was ingested under pancreatic clamp conditions, plasma insulin and glucagon concentrations remained unchanged, and the increase in plasma FFA and ketone concentrations was completely blocked, while the increase in EGP persisted. Total-body NE turnover rate was greater in subjects receiving empagliflozin (+67\\%) compared with placebo under both fasting and pancreatic clamp conditions. No difference in plasma NE concentration was observed in either study.The decrease in plasma insulin and increase in plasma glucagon concentration caused by empagliflozin is responsible for the increase in plasma FFA concentration and ketone production. The increase in EGP caused by empagliflozin is independent of the change in plasma insulin or glucagon concentrations and is likely explained by the increase in NE turnover.}},issn={0149-5992},doi={10.2337/dc22-0885},url={https://doi.org/10.2337/dc22-0885},note={dc220885},eprint={https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc22-0885/699841/dc220885.pdf}} . Diabetes Care.

Ahmed Khattab, Ali Torkamani(2022). Nidogen-1 could play a role in diabetic kidney disease development in type 2 diabetes: a genome-wide association meta-analysis . Human Genomics. 16. (1). Springer Science and Business Media {LLC}

Ricardo J. Samms and Christine C. Cheng and Marcel Fourcaudot and Sami Heikkinen and Ahmed Khattab and John Adams and Eugenio Cersosimo and Curtis Triplitt and Curtis Puckett and Kostas Tsintzas and Andrew Charles Adams and Muhammad A Abdul-Ghani and Ralph A. DeFronzo and Luke Norton(2022). FGF21 Contributes to Metabolic Improvements Elicited by Exenatide and Pioglitazone in Patients with Type 2 Diabetes . American Journal of Physiology-Endocrinology and Metabolism. American Physiological Society

(2020). Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT . Diabetes care.

PREPRINT

Ahmed Khattab, Shang-Fu Chen, Nathan Wineinger, Ali Torkamani (2024). AoUPRS: A Cost-Effective and Versatile PRS Calculator for theAll of UsProgram .

Ahmed Khattab, Shang-Fu Chen, Hossein Javedani Sadaei, Nathan Wineinger, Ali Torkamani (2024). A Two-Stage Machine Learning Approach for Personalized Type 2 Diabetes Screening Across Diverse Populations .

Ahmed Khattab, Ali Torkamani, Shang-Fu Chen, Sang Eun Lee, Hossein Sadaei, Jun-Bean Park, Corneliu Henegar, Nathan Wineinger, Evan Muse (2023). Meta-Prediction of Coronary Artery Disease Risk .

Ahmed Khattab, Ivan A. Valdez, Juan Pablo Palavicini, Terry M. Bakewell, Marcel Fourcaudot, Iriscilla Ayala, Ziying Xu, Xianlin Han, Chris E. Shannon, Luke Norton, et al.(2022). Persistent Inflammatory Lipotoxicity Impedes Pancreatic β-cell Function in Diet-Induced Obese Mice Despite Correction of Glucotoxicity . []. Cold Spring Harbor Laboratory